Addex Therapeutics (ADXN) Competitors $7.28 -0.52 (-6.65%) As of 02/21/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ADXN vs. MRNS, PMN, VRCA, SNYR, LEXX, AKTX, XLO, GDTC, BFRG, and JATTShould you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include Marinus Pharmaceuticals (MRNS), ProMIS Neurosciences (PMN), Verrica Pharmaceuticals (VRCA), Synergy CHC Corp. (Uplisting) (SNYR), Lexaria Bioscience (LEXX), Akari Therapeutics (AKTX), Xilio Therapeutics (XLO), CytoMed Therapeutics (GDTC), Bullfrog AI (BFRG), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry. Addex Therapeutics vs. Marinus Pharmaceuticals ProMIS Neurosciences Verrica Pharmaceuticals Synergy CHC Corp. (Uplisting) Lexaria Bioscience Akari Therapeutics Xilio Therapeutics CytoMed Therapeutics Bullfrog AI JATT Acquisition Addex Therapeutics (NASDAQ:ADXN) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment. Which has stronger valuation & earnings, ADXN or MRNS? Addex Therapeutics has higher earnings, but lower revenue than Marinus Pharmaceuticals. Addex Therapeutics is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAddex Therapeutics$1.83M4.35-$11.76M-$0.34-22.07Marinus Pharmaceuticals$30.99M0.98-$141.40M-$2.47-0.22 Does the media refer more to ADXN or MRNS? In the previous week, Marinus Pharmaceuticals had 1 more articles in the media than Addex Therapeutics. MarketBeat recorded 1 mentions for Marinus Pharmaceuticals and 0 mentions for Addex Therapeutics. Addex Therapeutics' average media sentiment score of 0.00 equaled Marinus Pharmaceuticals'average media sentiment score. Company Overall Sentiment Addex Therapeutics Neutral Marinus Pharmaceuticals Neutral Do analysts prefer ADXN or MRNS? Addex Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 299.73%. Marinus Pharmaceuticals has a consensus price target of $4.79, indicating a potential upside of 771.56%. Given Marinus Pharmaceuticals' higher probable upside, analysts clearly believe Marinus Pharmaceuticals is more favorable than Addex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Marinus Pharmaceuticals 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36 Does the MarketBeat Community believe in ADXN or MRNS? Marinus Pharmaceuticals received 422 more outperform votes than Addex Therapeutics when rated by MarketBeat users. Likewise, 66.62% of users gave Marinus Pharmaceuticals an outperform vote while only 51.72% of users gave Addex Therapeutics an outperform vote. CompanyUnderperformOutperformAddex TherapeuticsOutperform Votes1551.72% Underperform Votes1448.28% Marinus PharmaceuticalsOutperform Votes43766.62% Underperform Votes21933.38% Is ADXN or MRNS more profitable? Addex Therapeutics has a net margin of 850.30% compared to Marinus Pharmaceuticals' net margin of -446.48%. Addex Therapeutics' return on equity of -112.43% beat Marinus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Addex Therapeutics850.30% -112.43% -77.95% Marinus Pharmaceuticals -446.48%-7,831.35%-120.74% Which has more volatility and risk, ADXN or MRNS? Addex Therapeutics has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Do insiders and institutionals have more ownership in ADXN or MRNS? 16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 98.8% of Marinus Pharmaceuticals shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by company insiders. Comparatively, 5.5% of Marinus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryAddex Therapeutics and Marinus Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXN vs. The Competition Export to ExcelMetricAddex TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.26M$7.06B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-22.075.8226.1519.13Price / Sales4.35268.05435.3370.72Price / CashN/A65.6738.0134.83Price / Book6.256.717.644.62Net Income-$11.76M$138.55M$3.19B$245.94M7 Day Performance0.13%-2.63%-2.11%-2.62%1 Month Performance-2.53%-2.33%-0.49%-2.15%1 Year Performance-29.66%-5.33%16.44%12.95% Addex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXNAddex Therapeutics2.5244 of 5 stars$7.51-3.8%$30.00+299.7%-25.0%$8.26M$1.83M-22.0730MRNSMarinus Pharmaceuticals4.2119 of 5 stars$0.55+0.1%$4.79+770.1%-94.4%$30.37M$31.47M-0.22110Analyst ForecastPMNProMIS Neurosciences0.3443 of 5 stars$0.93-5.0%N/A-62.4%$30.27MN/A-9.265News CoverageVRCAVerrica Pharmaceuticals3.9342 of 5 stars$0.66-0.7%$9.50+1,342.0%-85.2%$30.04M$5.12M-0.3640Gap UpSNYRSynergy CHC Corp. (Uplisting)N/A$3.43-10.7%$10.00+191.5%N/A$29.86M$26.01M0.0040Gap UpLEXXLexaria Bioscience3.4102 of 5 stars$1.70-4.5%$9.50+458.8%-35.6%$29.84M$460,000.00-3.407AKTXAkari TherapeuticsN/A$1.12-9.4%N/A-58.6%$29.76MN/A0.009Analyst ForecastNews CoverageGap DownXLOXilio Therapeutics3.2453 of 5 stars$0.67-1.5%$4.00+497.0%+63.2%$29.45MN/A-0.3970GDTCCytoMed Therapeutics2.2476 of 5 stars$2.69-4.3%$5.00+85.9%+18.1%$29.43MN/A0.00N/ABFRGBullfrog AI0.2526 of 5 stars$3.36+17.5%N/A-32.1%$29.27M$60,000.00-3.954High Trading VolumeJATTJATT AcquisitionN/A$1.66-6.2%N/A-61.9%$28.64MN/A0.003Gap UpHigh Trading Volume Related Companies and Tools Related Companies Marinus Pharmaceuticals Alternatives ProMIS Neurosciences Alternatives Verrica Pharmaceuticals Alternatives Synergy CHC Corp. (Uplisting) Alternatives Lexaria Bioscience Alternatives Akari Therapeutics Alternatives Xilio Therapeutics Alternatives CytoMed Therapeutics Alternatives Bullfrog AI Alternatives JATT Acquisition Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADXN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
